Von Willebrand disease laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
|-
|-
|low vWD or possible Type 1
|low vWD or possible Type 1
|30-50 IU
|30-50 IU<ref name="pmid25673639">{{cite journal |vauthors=Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, van der Bom JG, Coppens M, de Meris J, Laros-van Gorkom BA, Mauser-Bunschoten EP, Leebeek FW, Eikenboom J |title=von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease |journal=Blood |volume=125 |issue=19 |pages=3006–13 |year=2015 |pmid=25673639 |doi=10.1182/blood-2014-09-603241 |url=}}</ref>
 
|-
|-
|1
|1

Revision as of 15:48, 28 December 2016

Von Willebrand disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Von Willebrand disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Von Willebrand disease laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Von Willebrand disease laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Von Willebrand disease laboratory findings

on Von Willebrand disease laboratory findings

Von Willebrand disease laboratory findings in the news

Blogs on Von Willebrand disease laboratory findings

Directions to Hospitals Treating Von Willebrand disease

Risk calculators and risk factors for Von Willebrand disease laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Prince Tano Djan, BSc, MBChB [2]

Overview

Laboratory Findings

The diagnosis of von Willebrand’s disease (VWD) begins with a relevant personal or family history of mucocutaneous bleeding. When VWD is suspected, several levels of testing are needed in order to make diagnosis as shown below:[1][2][3][4]

Initial tests:

  1. VWF antigen (VWF:Ag) level
  2. Factor VIII activity (FVIII:C).
  3. VWF–ristocetin cofactor activity [VWF:RCo] as a measure of platelet-binding activity of VWF
  • The VWF:RCo assay may be replaced by newer assays that measure the binding of VWF to a recombinant wild-type GPIb fragment with the use of ristocetin or the spontaneous binding of VWF to a gain-of-function recombinant mutant GPIb fragment.
Type vWF antigen level
low vWD or possible Type 1 30-50 IU[3]
1 <30 IU
2 Ratio of von Willebrand factor–ristocetin cofactor activity to von Willebrand factor antigen ≤0.6
3 < 5 IU[5][3]
  • When the results of all first-level tests are normal, VWD is ruled out; because of biologic variability, however, the tests should be repeated if values are at the low end of the normal range or if VWD is strongly suspected.[3]
  • If these first-level tests reveal definitive abnormalities, a diagnosis of VWD can be made; if the results are not conclusive, second-level tests are required.
  • Persons with a bleeding tendency who have VWF levels between 30 and 50 IU per deciliter (the lower limit of the normal range) are classified as having “low VWF” or “possible type 1 disease” but are not classified as having definitive VWD.[3]
  • When von Willebrand factor antigen is undetectable (or the level is <5 IU per deciliter, according to the latest disease classification), type 3 von Willebrand’s disease is diagnosed[5][3]
  • A proportional decrease in von Willebrand factor antigen and von Willebrand factor–ristocetin cofactor activity fits the diagnosis of type 1 von Willebrand’s disease.
  • A disproportional reduction in von Willebrand factor–ristocetin cofactor activity as compared with von Willebrand factor antigen (ratio of von Willebrand factor–ristocetin cofactor activity to von Willebrand factor antigen, ≤0.6) indicates type 2 disease.
  • Further subtyping tests, such as assays of von Willebrand factor multimers and ristocetin-induced platelet aggregation, are then required to determine the phenotypic characteristics that define types 2A, 2B, and 2M.
  • VWD can be subtyped on the basis of these second-level tests to enable appropriate choice of therapy.

Second-level tests

Second level tsets include the following:

  1. VWF multimer distribution using gel electrophoresis
  2. Ristocetin-induced platelet aggregation (RIPA)
  • A rare platelet defect due to a gain-of-function mutation in the GPIbα receptor, known as platelet-type VWD, has a phenotype similar to that of type 2B VWD; the two disorders can be distinguished with the use of genetic testing.
  • A platelet aggregation assay will show an abnormal response to ristocetin with normal responses to the other agonists used. A platelet function assay (PFA) will give an abnormal collagen/adrenaline closure time and in most cases (but not all) a normal collagen/ADP time. Type 2N can only be diagnosed by performing a "factor VIII binding" assay. Detection of vWD is complicated by vWF being an acute phase reactant with levels rising in infection, pregnancy and stress.

Other tests

Other tests performed in any patient with bleeding problems are:

Other coagulation factor assays may be performed depending on the results of a coagulation screen.

  • Patients with Von Willebrand disease will typically display a normal prothrombin time and a variable prolongation of partial thromboplastin time.

References

  1. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMID 25858564.
  2. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR (2011). "Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD". Blood. 117 (6): e67–74. doi:10.1182/blood-2010-08-299016. PMC 3056647. PMID 21148813.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, van der Bom JG, Coppens M, de Meris J, Laros-van Gorkom BA, Mauser-Bunschoten EP, Leebeek FW, Eikenboom J (2015). "von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease". Blood. 125 (19): 3006–13. doi:10.1182/blood-2014-09-603241. PMID 25673639.
  4. F. Stufano, A. S. Lawrie, S. La Marca, C. Berbenni, L. Baronciani & F. Peyvandi (2014). "A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen". Haemophilia : the official journal of the World Federation of Hemophilia. 20 (1): 147–153. doi:10.1111/hae.12264. PMID 24028703. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB (2006). "Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor". J. Thromb. Haemost. 4 (10): 2103–14. doi:10.1111/j.1538-7836.2006.02146.x. PMID 16889557.

Template:WH Template:WS